Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers

Next Previous
X
Search
Trial Profile

A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Pegenzileukin (Primary) ; Tebentafusp (Primary)
  • Indications Carcinoma; Malignant melanoma; Skin cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 20 Feb 2024 Planned End Date changed from 27 Jan 2025 to 11 Feb 2025.
    • 29 Aug 2023 Planned End Date changed from 5 Jun 2026 to 27 Jan 2025.
    • 14 Feb 2023 Planned primary completion date changed from 7 Mar 2024 to 22 Aug 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top